New combo therapy aims to slash liver cancer recurrence before surgery
NCT ID NCT07522411
First seen Apr 24, 2026 · Last updated May 03, 2026 · Updated 2 times
Summary
This study tests whether giving a combination of drugs (sintilimab, bevacizumab, and chemotherapy) along with liver-directed treatments before surgery can reduce the risk of liver cancer returning in patients with high-risk features. About 100 adults with resectable liver cancer will be randomly assigned to either the pre-surgery combination therapy followed by surgery, or surgery alone. The main goal is to see if the combination improves the chance of being cancer-free two years after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.